Pipeline

Immunethep has developed the Paragon Novel Vaccine (PNV) concept, a breakthrough product line of vaccines providing effective protection against bacterial infections caused by multiple bacteria: 

PNV_Ent - Escherichia coli, and Klebsiella pneumoniae;

PNV_Strep - Streptococcus pneumoniae, Streptococcus agalactiae (GBS, and Streptococcus pyogenes.

PNV_Staph - Staphylococcus aureus (MRSA and VRSA), and Staphylococcus epidermis;

PNV works by neutralising an extracellular form of bacterial GAPDH, without blocking the human GAPDH. This will enable the host immune system to fight the infection and eliminate the bacteria. 

Preclinical trials performed on animal models have demonstrated high levels of efficacy against the bacteria with a strong safety profile. 

PNV is a peptide-based immunotherapy that is stable at high temperatures and not freezing sensitive.

Once on the market, the PNV vaccines will become the world’s first vaccines preventing multiple bacterial infections for all its invasive serotypes, including multi-resistant strains.

Immunethep is developing a set of therapeutic immunotherapies based on monoclonal antibodies targeting bacterial infections caused by multiple bacteria: 

UNImAb_Ent - Escherichia coli, and Klebsiella pneumoniae;

UNImAb_Strep - Streptococcus pneumoniae, Streptococcus agalactiae (GBS, and Streptococcus pyogenes.

UNImAb_Staph - Staphylococcus aureus (MRSA and VRSA), and Staphylococcus epidermis;

The UNImAb monoclonal antibodies present the following characteristics:

• Monoclonal antibody (IgG1) targeting bacterial GAPDH;
• Treats infection from all invasive serotypes of multiple bacteria;
• Very low probability of inducing resistance;
• Microbiome friendly